Skip to Content
Merck
CN
  • Modification of selected anti-HCMV drugs with lipophilic boron cluster modulator.

Modification of selected anti-HCMV drugs with lipophilic boron cluster modulator.

Acta poloniae pharmaceutica (2013-06-14)
Agnieszka B Olejniczak, Anna M Adamska, Edyta Paradowska, Mirosława Studzinska, Patrycja Suski, Zbigniew J Leśnikowski
ABSTRACT

Methods for the modification of ganciclovir (GCV), acyclovir (ACV), cidofovir (CDV) and valganciclovir (VCDV) with boron cluster have been developed. Toxicity of the new derivatives was evaluated in adherent cells; no cytotoxicity was observed in five different cell lines up to 1000 microM with the exception of modified valganciclovir which was cytotoxic above 300 microM. The compounds were active against HCMV or HSV-1 by cytopathic effect or plaque reduction assays. None of the tested compounds had activity against HPIV-3 or VSV.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Boron, crystalline, −60 mesh, 99% trace metals basis
Sigma-Aldrich
Boron, ≥95% (boron), amorphous powder
Sigma-Aldrich
Boron, crystalline, 1 cm, 99.7% trace metals basis